MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Lorenc, K. R., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22, S406–S407. https://doi.org/10.1016/s2152-2650(22)01591-9
Authors:
Jeffrey A. Zonder
Joshua Richter
Naresh Bumma
Jason Brayer
James E. Hoffman
William I. Bensinger
Ka Lung Wu
Linzhi Xu
Dhruti Chokshi
Anita Boyapati
Damien Cronier
Yariv Houvras
Karen Rodriguez Lorenc
Glenn S. Kroog
Madhav V. Dhodapkar
Suzanne Lentzsch
Dennis Cooper
Sundar Jagannath
Affiliated Authors:
Suzanne Lentzsch
Author Keywords:
bispecific antibody
clinical trial
mm
multiple myeloma
phase i/ii
Publication Type:
Article
Unique ID:
10.1016/S2152-2650(22)01591-9
Publication Date:
Data Source:
Scopus

Record Created: